Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

(R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses
Panos Zanos, Jaclyn N. Highland, Xin Liu, et al.
British Journal of Pharmacology (2019) Vol. 176, Iss. 14, pp. 2573-2592
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
Kenji Hashimoto
Psychiatry and Clinical Neurosciences (2019) Vol. 73, Iss. 10, pp. 613-627
Open Access | Times Cited: 287
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Jordi Bonaventura, Sherry Lam, Meghan L. Carlton, et al.
Molecular Psychiatry (2021) Vol. 26, Iss. 11, pp. 6704-6722
Open Access | Times Cited: 210
Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites
Chun Yang, Jianjun Yang, Ailin Luo, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 164
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 164
Mechanisms of ketamine and its metabolites as antidepressants
Evan Hess, Lace M. Riggs, Michael Michaelides, et al.
Biochemical Pharmacology (2021) Vol. 197, pp. 114892-114892
Open Access | Times Cited: 117
Experimenters’ sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor
Polymnia Georgiou, Panos Zanos, Ta-Chung M. Mou, et al.
Nature Neuroscience (2022) Vol. 25, Iss. 9, pp. 1191-1200
Open Access | Times Cited: 101
Ketamine in neuropsychiatric disorders: an update
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 23-40
Closed Access | Times Cited: 48
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Bashkim Kadriu, Maximillian Greenwald, Ioline D. Henter, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 1, pp. 8-21
Open Access | Times Cited: 81
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Jaclyn N. Highland, Panos Zanos, Lace M. Riggs, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 2, pp. 763-791
Open Access | Times Cited: 75
Ketamine and the Future of Rapid-Acting Antidepressants
Lace M. Riggs, Todd D. Gould
Annual Review of Clinical Psychology (2021) Vol. 17, Iss. 1, pp. 207-231
Open Access | Times Cited: 62
The abuse liability of ketamine: A scoping review of preclinical and clinical studies
Tuyen T. Le, Isabel Pazos Cordero, Muhammad Youshay Jawad, et al.
Journal of Psychiatric Research (2022) Vol. 151, pp. 476-496
Closed Access | Times Cited: 45
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
Anees Bahji, Carlos A. Zarate, Gustavo Vázquez
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 853-866
Open Access | Times Cited: 40
Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study
Gustavo C. Leal, Breno Souza‐Marques, Rodrigo P. Mello, et al.
Journal of Affective Disorders (2023) Vol. 330, pp. 7-15
Closed Access | Times Cited: 38
Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants
Tao Chen, Ling Cheng, Jingwen Ma, et al.
Pharmacological Research (2023) Vol. 194, pp. 106837-106837
Open Access | Times Cited: 26
Rapid hippocampal synaptic potentiation induced by ketamine metabolite (2R,6R)-hydroxynorketamine persistently primes synaptic plasticity
Kyle A. Brown, Musa Iyiola Ajibola, Todd D. Gould
Neuropsychopharmacology (2025)
Open Access | Times Cited: 1
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
Cristan Farmer, Jessica R. Gilbert, Ruin Moaddel, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 8, pp. 1398-1404
Open Access | Times Cited: 69
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
Jordi Bonaventura, Juan L. Gomez, Meghan L. Carlton, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 10, pp. 4144-4156
Open Access | Times Cited: 31
Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications
Senbing Zhang, Yanzhu Pu, Jianning Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)‐Hydroxynorketamine in Healthy Volunteers
Shruti M. Raja, Jeffrey T. Guptill, Michelle Mack, et al.
Clinical Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 7
(S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression
Rei Yokoyama, Momoko Higuchi, Wataru Tanabe, et al.
Pharmacology Biochemistry and Behavior (2020) Vol. 191, pp. 172876-172876
Closed Access | Times Cited: 49
Rodent ketamine depression-related research: Finding patterns in a literature of variability
Andrew J. Polis, Paul J. Fitzgerald, Pho J. Hale, et al.
Behavioural Brain Research (2019) Vol. 376, pp. 112153-112153
Open Access | Times Cited: 46
The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL/6J mice
Anna Rafało-Ulińska, Agnieszka Pałucha-Poniewiera
Behavioural Brain Research (2021) Vol. 418, pp. 113633-113633
Closed Access | Times Cited: 38
Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers
Ellen Scotton, Bárbara Antqueviezc, Mailton Vasconcelos, et al.
Biochemical Pharmacology (2022) Vol. 198, pp. 114963-114963
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top